The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

In recent decades, immunotherapy has transformed cancer treatment, offering effective options for diseases once considered ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

(NASDAQ: NASDAQ:REPL), a biotechnology firm engaged in developing oncolytic immunotherapies, has applied for FDA approval for its advanced melanoma treatment, RP1, in combination with nivolumab.

The number of Canadians diagnosed with melanoma each year has more than tripled in the past three decades. An estimated ...

Over a period of six years, Ernesto Rogata underwent extensive treatment to rid him of cancer. By the time of diagnosis, what ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

CHARLOTTESVILLE, Va. (CBS19 NEWS) -- A research team at UVA Health is investigating the ability of focused ultrasound to help treat melanoma. In their trial, the researchers want to see whether the ...

If a doctor does determine you have melanoma, it’s very curable if treated ... listening to their concerns and creating a treatment plan with each patient's priorities and real life in mind.

Brain metastases occur in as many as 50% of patients with melanoma and are associated with an "abysmal prognosis," said ...

Shares of Replimune Group topped recent 52-week highs in the after-hours market, following news the company received breakthrough therapy designation for its RP1 and submitted a biologics license ...

Malignant melanoma is the fastest-growing and 7th ... (which may be pigmented as in acne scars after prolonged minocycline treatment), and seborrheic keratoses. The multidisciplinary team may ...